Nine biologics are approved to treat rheumatoid arthritis (RA), along with an oral Jak inhibitor Xeljanz (Pfizer). Given rheumatologists’ long-standing familiarity with the safety and efficacy profiles of the TNF-alpha inhibitors and non-TNF-alpha biologics Orencia (Bristol-Myers Squibb), Rituxan/MabThera (Biogen/Roche), and RoActemra/Actemra (Roche), new agents face formidable challenges in gaining uptake in this crowded market. Nonetheless, all marketed RA drugs are associated with substantial nonresponder rates, highlighting a significant unmet need and commercial opportunity for novel therapies that can offer improved efficacy and safety.


Related Reports

Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOKRheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone des...

View Details

Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast

View Details

Rheumatoid Arthritis - Unmet Need - Detailed, Expanded Analysis: TNF-alpha Refractory Rheumatoid Arthritis (US & EU )

Rheumatoid arthritis (RA) patients refractory to one or more tumor necrosis factor-alpha (TNF-α) inhibitor...

View Details

Rheumatoid Arthritis - Geographic Focus - China - Rheumatoid Arthritis - China In-Depth - China

MARKET OUTLOOKRheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily...

View Details